eIF3a

A new anticancer drug target in the eIF family

Ji Ye Yin, Jian-Ting Zhang, Wei Zhang, Hong Hao Zhou, Zhao Qian Liu

Research output: Contribution to journalShort survey

3 Citations (Scopus)

Abstract

eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalCancer Letters
Volume412
DOIs
StatePublished - Jan 1 2018

Fingerprint

Physiological Phenomena
Proto-Oncogenes
Pathologic Processes
Pharmaceutical Preparations
Neoplasms
Carcinogenesis
Neoplasm Metastasis
Therapeutics

Keywords

  • Anticancer
  • Drug target
  • eIF3a
  • Translation initiation
  • Translation regulation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yin, J. Y., Zhang, J-T., Zhang, W., Zhou, H. H., & Liu, Z. Q. (2018). eIF3a: A new anticancer drug target in the eIF family. Cancer Letters, 412, 81-87. https://doi.org/10.1016/j.canlet.2017.09.055

eIF3a : A new anticancer drug target in the eIF family. / Yin, Ji Ye; Zhang, Jian-Ting; Zhang, Wei; Zhou, Hong Hao; Liu, Zhao Qian.

In: Cancer Letters, Vol. 412, 01.01.2018, p. 81-87.

Research output: Contribution to journalShort survey

Yin, JY, Zhang, J-T, Zhang, W, Zhou, HH & Liu, ZQ 2018, 'eIF3a: A new anticancer drug target in the eIF family', Cancer Letters, vol. 412, pp. 81-87. https://doi.org/10.1016/j.canlet.2017.09.055
Yin, Ji Ye ; Zhang, Jian-Ting ; Zhang, Wei ; Zhou, Hong Hao ; Liu, Zhao Qian. / eIF3a : A new anticancer drug target in the eIF family. In: Cancer Letters. 2018 ; Vol. 412. pp. 81-87.
@article{1d9e75b776174e0abd23e2f3cdedfe1c,
title = "eIF3a: A new anticancer drug target in the eIF family",
abstract = "eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.",
keywords = "Anticancer, Drug target, eIF3a, Translation initiation, Translation regulation",
author = "Yin, {Ji Ye} and Jian-Ting Zhang and Wei Zhang and Zhou, {Hong Hao} and Liu, {Zhao Qian}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2017.09.055",
language = "English (US)",
volume = "412",
pages = "81--87",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - eIF3a

T2 - A new anticancer drug target in the eIF family

AU - Yin, Ji Ye

AU - Zhang, Jian-Ting

AU - Zhang, Wei

AU - Zhou, Hong Hao

AU - Liu, Zhao Qian

PY - 2018/1/1

Y1 - 2018/1/1

N2 - eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.

AB - eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.

KW - Anticancer

KW - Drug target

KW - eIF3a

KW - Translation initiation

KW - Translation regulation

UR - http://www.scopus.com/inward/record.url?scp=85032175973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032175973&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.09.055

DO - 10.1016/j.canlet.2017.09.055

M3 - Short survey

VL - 412

SP - 81

EP - 87

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -